Huilgol N G, Nair C K K, Merhotra P, Kagiya V T
Division of Radiation Oncology, Nanavati Hospital, Vile Parle (W), Mumbai, India.
J Cancer Res Ther. 2005 Jan-Mar;1(1):38-40. doi: 10.4103/0973-1482.16089.
To evaluate Tocoferol monoglucoside (TMG), a water soluble vit. E. in a phase I trial, as a radiation protector in those undergoing hemi-body radiation for disseminated disease.
Patients scheduled to receive modified hemi-body radiation were accrued for the study. Patients not only had disseminated skeletal disease but, were heavily pretreated Seven patients were accrued for the study. Patients received 1 and 2 gms of TMG. 30-40 minutes before hemibody radiation. A dose of 600 cGy was delivered on telecobalt equipment at mid plane. Immediate Toxicities were evaluated as well as response to pain.
All the seven patients underwent radiation uneventfully. There was no drug related toxicity. Pain relief was adequate.
Tocoferol monoglucoside an effective antioxidant with no significant acute toxicity, when administered in a dose of 1 or 2 gms per oral route. TMG being water-soluble can have global antioxidant and radio protective effects. This needs further clinical evaluation.
在一项I期试验中评估生育酚单葡萄糖苷（TMG），一种水溶性维生素E，作为接受半身放疗治疗播散性疾病患者的辐射防护剂。
招募计划接受改良半身放疗的患者进行该研究。患者不仅患有播散性骨骼疾病，而且此前接受过大量治疗。招募了7名患者进行该研究。患者在半身放疗前30 - 40分钟接受1克和2克的TMG。通过远距离钴设备在中平面给予600厘戈瑞的剂量。评估即时毒性以及对疼痛的反应。
所有7名患者放疗过程顺利。没有与药物相关的毒性。疼痛缓解充分。
生育酚单葡萄糖苷是一种有效的抗氧化剂，口服剂量为1克或2克时无明显急性毒性。TMG具有水溶性，可产生全身抗氧化和辐射防护作用。这需要进一步的临床评估。
